Open Access Open Access  Restricted Access Subscription Access

Understanding Opioid Antagonists: Mechanisms and Implications

Muralinath E., Pooja Devi, Prasanta Chbukdhara, Sanjib Borah, Kalyan C., Archana Jain, Guruprasad M.

Abstract


Opioid antagonists play an important role in the field of pharmacology especially regarding management of pain. Opioid receptors are integral components of the body's endogenous pain control system. Opioid antagonists stop these Opioid receptors and block the activation of Opioid pathways. The primary Opioid antagonist is naloxone that behaves by competitively binding with opioid receptors. Naltrexone is another opioid antagonist with a longer duration of action than naloxone. Naltrexone is helpful on the long_ term treatment of opioid dependence. Naltrexone plays a major tmrole in decreasing alcohol consumption and stopping relapse in individuals with alcohol use disorder. Opioid antagonists primarily play a major role especially in mood disorders, pain management and even immune modulation. Factors namely genetics, overall health and the specific opioids participated influence the effectiveness of antagonists and the potential for side effects. Finally it is decided that opioid antagonists exhibit a critical component of the pharmacological toolkit particularly for managing opioid _ related emergencies as well as substance use disorders.

 


Full Text:

PDF

References


Waldhoer, M., Bartlett, S. E., & Whistler, J. L. (2004). Opioid receptors. Annual review of biochemistry, 73(1), 953-990.2.

Sridharan, K., & Sivaramakrishnan, G. (2018). Drugs for treating opioid-induced constipation: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials. Journal of pain and symptom management, 55(2), 468-479.

Karkhanis, A., Holleran, K. M., & Jones, S. R. (2017). Dynorphin/kappa opioid receptor signaling in preclinical models of alcohol, drug, and food addiction. International review of neurobiology, 136, 53-88.

Varga, E. V., Navratilova, E., Stropova, D., Jambrosic, J., Roeske, W. R., & Yamamura, H. I. (2004). Agonist-specific regulation of the δ-opioid receptor. Life sciences, 76(6), 599-612.

Thomas, J., Karver, S., Cooney, G. A., Chamberlain, B. H., Watt, C. K., Slatkin, N. E., ... & Israel, R. J. (2008). Methylnaltrexone for opioid-induced constipation in advanced illness. New England Journal of Medicine, 358(22), 2332-2343.

Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., ... & Ozonoff, A. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. Bmj, 346.

Stein, C., & Lang, L. J. (2009). Peripheral mechanisms of opioid analgesia. Current opinion in pharmacology, 9(1), 3-8.

Hassanian-Moghaddam, H., Afzali, S., & Pooya, A. (2014). Withdrawal syndrome caused by naltrexone in opioid abusers. Human & experimental toxicology, 33(6), 561-567.

Fishbain, D. A., Goldberg, M., Rosomoff, R. S., & Rosomoff, H. (1988). Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification. Journal of clinical psychopharmacology, 8(6), 441.10.

Bisaga, A., Mannelli, P., Sullivan, M. A., Vosburg, S. K., Compton, P., Woody, G. E., & Kosten, T. R. (2018). Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies. The American journal on addictions, 27(3), 177-187.

Johnson, B. A. (2007). Naltrexone long-acting formulation in the treatment of alcohol dependence. Therapeutics and clinical risk management, 3(5), 741-749.]

Comer, S. D., Sullivan, M. A., Vosburg, S. K., Manubay, J., Amass, L., Cooper, Z. D., ... & Kleber, H. D. (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine‐maintained intravenous heroin abusers. Addiction, 105(4), 709-718.


Refbacks

  • There are currently no refbacks.